Phio Pharmaceuticals Corp. PHIO
Set alert
0.86 USD 0.00 -0.30%
At close · Oct 30
0.88 +0.02 +1.94%
After hours · Oct 30, 4:00 PM ET
0.85 Day range 0.8767
0.85 52-week range 2.06
- YTD
- -18.10%
- 1 year
- -58.25%
- Open
- 0.86
- Prev close
- 0.8626
- Mkt cap
- 9.99M
- Vol
- 66.66K
- Avg vol
- 128.05K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.85
- High
- 0.8767
- Forward P/E
- 0.07
- Beta
- 1.47
- Short ratio
- 0.50
- Inst. own
- 3.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.76
- 200-d avg
- 4.62
- 1y target
- 0.00
5Y chart
Events in this range
- Jan 26, 2023Split: 1 for 12
- Aug 10, 2023Earnings: -13.23; estimate 0; surprise —%
- Aug 16, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Nov 9, 2023Earnings: -10.26; estimate -12.87; surprise 20.28%
- Feb 6, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Apr 1, 2024Earnings: -1.53; estimate 0; surprise —%
- May 9, 2024Earnings: -4.23; estimate 0; surprise —%
- May 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jul 5, 2024Split: 1 for 9
- Aug 14, 2024Earnings: -3.62; estimate -4.59; surprise 21.13%
- Nov 14, 2024Earnings: -1.54; estimate 0; surprise —%
Signals (66)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 16, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 9, 2026 | 8 months ago |
| MACD: Sell Signal | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bearish | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Dec 16, 2024 | 1 year ago |
| SMA: Bullish | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Oct 7, 2024 | 2 years ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 9, 2024 | 2 years ago |
| RSI: Oversold | Aug 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 29, 2024 | 2 years ago |
| RSI: Oversold | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| SMA: Bearish | May 6, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 9, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| RSI: Oversold | Sep 11, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 21, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Apr 10, 2023 | 3 years ago |
| SMA: Bullish | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 2, 2023 | 3 years ago |
| RSI: Oversold | Dec 12, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 7, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 17, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 10, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Jul 18, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| RSI: Overbought | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 2.35M
- Enterprise value
- -2.80M
- Trailing P/E
- 0.00
- Forward P/E
- 0.07
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.12
- EPS (TTM)
- -9.75
- Beta
- 1.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.73M
- Total cash
- 4.70M
- Total debt
- 0
- Return on equity
- -126.86%
- Shares outstanding
- 1.06M
- Short % of float
- 6.00%
- 50-day average
- 2.76
- 200-day average
- 4.62
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PHIO Revenue — quarterly 0
PHIO Net income — quarterly -4.14M
PHIO EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.54 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -4.59 | -3.62 | +0.97 | +21.13% |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -4.23 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -1.53 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -12.87 | -10.26 | +2.61 | +20.28% |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -13.23 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 16, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- phiopharma.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
- Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
- Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2b
- Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
- Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
- Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
- Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
- Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target
Your note
Sign in to keep a note on PHIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BITTERMAN ROBERT J | Chief Executive Officer | Stock Award(Grant) | Sep 10, 2024 | 17,832 |
| BRADFORD PATRICIA A | Director | Stock Award(Grant) | Sep 10, 2024 | 8,000 |
| CAUWENBERGH GEERT | Director | Stock Award(Grant) | Feb 16, 2023 | 4,235 |
| FERRARA ROBERT L | Director | Stock Award(Grant) | Sep 10, 2024 | 10,000 |
| FREEMAN JONATHAN E PH.D. | Director | Stock Award(Grant) | Sep 10, 2024 | 1,000 |
| KONTULIS CAITLIN | Officer | Stock Award(Grant) | Feb 16, 2023 | 12,494 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 2.38% | 25,131 | 56.04K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 1,685 | 3.76K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.11% | 1,174 | 2.62K | Sep 29, 2024 |
| Nordwand Advisors, LLC | 0.05% | 500 | 1.11K | Sep 29, 2024 |
| Activest Wealth Management | 0.00% | 9 | 20 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 7 | 15 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.41% | 4,290 | 9.57K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.26% | 2,707 | 6.04K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.15% | 1,582 | 3.53K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 4 | 8 | Sep 29, 2024 |